36.30
0.11%
+0.04
After Hours:
36.30
Celldex Therapeutics Inc. stock is currently priced at $36.30, with a 24-hour trading volume of 322.02K.
It has seen a +0.11% increased in the last 24 hours and a -11.55% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $36.42 pivot point. If it approaches the $35.69 support level, significant changes may occur.
Previous Close:
$36.26
Open:
$36.31
24h Volume:
322.02K
Market Cap:
$2.38B
Revenue:
$6.88M
Net Income/Loss:
$-141.43M
P/E Ratio:
-13.75
EPS:
-2.64
Net Cash Flow:
$-109.11M
1W Performance:
-4.42%
1M Performance:
-11.55%
6M Performance:
+55.79%
1Y Performance:
+12.28%
Celldex Therapeutics Inc. Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc.
Sector
Industry
Phone
908-200-7500
Address
Perryville III Building, Suite 220 53 Frontage Road, Hampton
Celldex Therapeutics Inc. Stock (CLDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-20-23 | Initiated | TD Cowen | Outperform |
Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Aug-22-23 | Initiated | Wells Fargo | Underweight |
Sep-17-21 | Initiated | Jefferies | Buy |
Sep-10-21 | Initiated | SVB Leerink | Outperform |
Jul-22-21 | Initiated | Guggenheim | Buy |
Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
Aug-01-17 | Resumed | H.C. Wainwright | Buy |
Nov-07-16 | Initiated | Aegis Capital | Buy |
Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
Mar-01-16 | Initiated | H.C. Wainwright | Buy |
Aug-11-15 | Reiterated | Brean Capital | Buy |
Aug-11-15 | Reiterated | Oppenheimer | Outperform |
Aug-11-15 | Reiterated | ROTH Capital | Buy |
Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
Nov-17-14 | Reiterated | ROTH Capital | Buy |
Mar-04-14 | Reiterated | Oppenheimer | Outperform |
Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
Feb-26-13 | Reiterated | Oppenheimer | Outperform |
Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
Oct-02-12 | Reiterated | Oppenheimer | Outperform |
Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc. Stock (CLDX) Latest News
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
GlobeNewswire Inc.
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Zacks Investment Research
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
Zacks Investment Research
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Zacks Investment Research
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
Zacks Investment Research
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
GlobeNewswire Inc.
Celldex Therapeutics Inc. Stock (CLDX) Financials Data
Celldex Therapeutics Inc. (CLDX) Revenue 2024
CLDX reported a revenue (TTM) of $6.88 million for the quarter ending December 31, 2023, a +192.02% rise year-over-year.
Celldex Therapeutics Inc. (CLDX) Net Income 2024
CLDX net income (TTM) was -$141.43 million for the quarter ending December 31, 2023, a -25.91% decrease year-over-year.
Celldex Therapeutics Inc. (CLDX) Cash Flow 2024
CLDX recorded a free cash flow (TTM) of -$109.11 million for the quarter ending December 31, 2023, a -3.36% decrease year-over-year.
Celldex Therapeutics Inc. (CLDX) Earnings per Share 2024
CLDX earnings per share (TTM) was -$2.92 for the quarter ending December 31, 2023, a -22.18% decline year-over-year.
About Celldex Therapeutics Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Cap:
|
Volume (24h):